Miguel Santiago Gonzalez

TL;DR: In this paper, a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms was conducted.

TL;DR: In this paper, the effect of high titers of IgG against N-protein on clinical outcomes of SARS-CoV2 disease has not been described, and the authors studied 400 RT-PCR confirmed SARS CoV2 patients to determine independent factors associated with poor outcomes, including Medical Intensive Care Unit (MICU) admission, prolonged MICU stay and hospital admissions, and in-hospital mortality.

TL;DR: It was shown that higher CCI and higher IL6 levels were independently associated with in-hospital mortality, and several factors, including Charlson comorbidity Index, high levels of IL6, and presentation with dyspnea were associated with poor clinical outcomes.

TL;DR: Early administration of high-titer convalescent plasma against SARS-CoV2 to mildly ill infected seniors reduced COVID-19 progression and facilitates access to treatment from industrialized to LMIC, can decompress demands on hospitals, and may contribute to save lives.